Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions

Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Capsules Administered as the Content of 2 x 25 mg Capsules Mixed With Applesauce in Healthy Subjects Under Fasting Conditions

The objective of this study was to compare the rate and extent of absorption or topiramate 25 mg capsules (test) versus Topamax® (reference) administered as the content of 2 x 25 mg capsules mixed with applesauce under fasting conditions.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Topiramate 25 mg Capsules; Other: Applesauce; Drug: Topamax® 25 mg Capsules

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Sainte-Foy, Quebec, Canada, G1V 2K8
      • Anapharm Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects will be females and/or males, non-smokers, 18 years of age or older
• Subjects should read, sign and date an Informed Consent Form prior to any study procedures.
• Female subjects will be post-menopausal or surgically sterilized.
• Post menopausal status is defined as absence of menses for the past 12 months or bilateral oophorectomy at least 6 months ago or hysterectomy with bilateral oophorectomy at least 6 months ago.
• Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation aat least 6 months ago.

Exclusion Criteria:

• Clinically significant illnesses within 4 weeks of the administration of study medication.
• Clinically significant surgery within 4 weeks prior to the administration of the study medication.
• Any history or presence of significant neurological, hepatic, renal, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
• Any clinically significant abnormality found during medical screening.
• Abnormal laboratory tests judged clinically significant.
• Positive urine drug screen at screening.
• Positive alcohol breath test at screening.
• Subjects who use tobacco in any form will not be eligible to participate in this study. Three months abstinence is required.
• Positive testing for hepatitis B, hepatitis C or HIV at screening.
• ECG or vital sign abnormalities (clinically significant).
• Subjects with BMI greater than or equal to 30.0.
• History of significant alcohol abuse within 6 months of the screening visit or any indication of the regular use of more than two units of alcohol per day (1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
• History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
• Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical subinvestigator, contraindicates the subjects participation in this study.
• History of allergic reactions to topiramate.
• Use of any drugs known to induce or inhibit hepatic drug metabolism, use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
• Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption.
• Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (500 mL) within 56 days prior to administration of the study medication.
• Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.

Additional exclusion criteria for females only:

• Positive urine pregnancy test at screening (performed on all females).

Study Plan

How is the study designed?

Design Details

• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Test First; Topiramate Capsules 25 mg	Drug: Topiramate 25 mg Capsules; Topiramate Capsules 2 x 25 mg; Other: Applesauce; Applesauce
ACTIVE_COMPARATOR: Reference First; Topamax® 25 mg Capsule	Other: Applesauce; Applesauce; Drug: Topamax® 25 mg Capsules; Topamax® Capsule 2 x 25 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax - Maximum Observed Concentration	Bioequivalence based on Cmax	Blood samples collected over 168 hour period
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)	Bioequivalence based on AUC0-inf	Blood samples collected over 168 hour period
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration	Bioequivalence based on AUC0-t	Blood samples collected over 168 hour period

Collaborators and Investigators

• Sponsor: Teva Pharmaceuticals USA

Study record dates

Study Major Dates

• Study Start: June 1, 2002
• Primary Completion (ACTUAL): July 1, 2002
• Study Completion (ACTUAL): July 1, 2002

Study Registration Dates

• First Submitted: May 18, 2009
• First Submitted That Met QC Criteria: May 19, 2009
• First Posted (ESTIMATE): May 20, 2009

Study Record Updates

• Last Update Posted (ESTIMATE): September 23, 2009
• Last Update Submitted That Met QC Criteria: August 14, 2009
• Last Verified: August 1, 2009

More Information

Terms related to this study

• Keywords: Bioequivalence; Healthy Subjects
• Additional Relevant MeSH Terms: Hypoglycemic Agents; Physiological Effects of Drugs; Anticonvulsants; Topiramate
• Other Study ID Numbers: 02136